Mucin-preserving strategies to reduce complications after stem cell transplant
Official title: Mucin preserving strategies to reduce allo HCT toxicities
Funded at Beckman Research Institute/city of Hope · NIH-11417315 · Data updated 2026-11-12
A patient-facing overview of a program aiming to protect gut mucus and reduce treatment-related complications after stem cell transplants.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | September 21, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $472,874 |
| NIH project number | 5P01HL170046-03 |
| Project ID | NIH-11417315 on NIH RePORTER |
Who could benefit from this research
✓Could help
People receiving allogeneic hematopoietic cell transplantation who are at risk for GVHD and related gut toxicities.
✕Less likely to help
Patients not undergoing allo HCT or those with conditions unlikely to be affected by gut mucin protection may not benefit.
What this research studies
This program looks at ways to keep the gut’s mucus layer intact during allo HCT, with the goal of lowering gut inflammation and infections. Researchers will study how antibiotics and gut bacteria affect the intestinal lining and transplant outcomes, using findings from prior work in humans and animal models. If successful, it could lead to safer transplant protocols that minimize GVHD and other toxic effects for patients undergoing allo HCT.
Why it matters
Potential benefit: If successful, patients receiving stem cell transplants could experience fewer serious gut-related complications and better overall recovery.
How similar studies have gone: Previous studies have linked gut bacteria and antibiotic use to GVHD and transplant-related toxicity, guiding this approach.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Jenq, Robert — Beckman Research Institute/city of Hope
- Study coordinator: Jenq, Robert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.